Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease.
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease.
Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2025 Sep; 23(10):1817-1823.
View in:
PubMed
subject areas
Adolescent
Adult
Antibodies, Monoclonal
C-Reactive Protein
Crohn Disease
Drug-Related Side Effects and Adverse Reactions
Feces
Female
Humans
Leukocyte L1 Antigen Complex
Male
Middle Aged
Prospective Studies
Tertiary Care Centers
Treatment Outcome
Young Adult
authors with profiles
David Rubin
Russell Cohen